Paper Review Records
全部论文审稿周期
30 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接
4
天
Ravulizumab Shows Favorable Survival and Improves Clinical Markers in Children With HSCT ‐ TMA : Results of a Phase 3 Trial
作者
Franco Locatelli; Michelle L. Schoettler; David Bueno‐Sánchez; Sonali Chaudhury; Jude Fry; Eric Bachman; Min Qin; Cynthia Carrillo‐Infante; Cory Williams; Aviva Krauss; Sarah Lawson; Yoshiyuki Takahashi; Hideki Sano; Daiichirou Hasegawa; Hyoung Jin Kang; Christopher C. Dvorak展开收起
作者单位
1. Department of Pediatric Hematology and Oncology Istituto di Ricovero e Cura a Carattere Scientifico Bambino Gesù Children's Hospital and Catholic University of the Sacred Heart Rome Italy; 2. Aflac Cancer and Blood Disorders Center Children's Healthcare of Atlanta and Emory University School of Medicine Atlanta Georgia USA; 3. Pediatric Hematology and Oncology Department La Paz University Hospital Madrid Spain; 4. Stem Cell Transplantation and Cellular Therapies Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine Chicago Illinois USA; 5. Alexion, AstraZeneca Rare Disease Baar Switzerland; 6. Alexion, AstraZeneca Rare Disease Boston Massachusetts USA; 7. Department of Hematology—Oncology Schneider Children's Medical Center of Israel Petah Tikva Israel; 8. Department of Oncology and Hematology Birmingham Children's Hospital National Health Service Foundation Trust Birmingham UK; 9. Department of Pediatrics Nagoya University Graduate School of Medicine Nagoya Japan; 10. Department of Pediatric Oncology Fukushima Medical University Hospital Fukushima Japan; 11. Hyogo Prefectural Kobe Children's Hospital Kobe Japan; 12. Department of Pediatrics, Seoul National University College of Medicine Seoul National University Cancer Research Institute, Seoul National University Children's Hospital Seoul Republic of Korea; 13. Division of Pediatric Allergy, Immunology, and Bone Marrow Transplantation University of California San Francisco San Francisco California USA展开收起
18
天
Is There an Association Between GLP ‐ 1RA Use and Blood Cancer Incidence or Progression?
作者
Hagop Kantarjian; Ayalew Tefferi展开收起
作者单位
1. Department of Leukemia The University of Texas, MD Anderson Cancer Center Houston Texas USA; 2. Division of Hematology, Department of Medicine Mayo Clinic Rochester Minnesota USA展开收起
9
天
Is Bone Marrow Examination Still Required at Diagnosis of Typical Chronic‐Phase Chronic Myeloid Leukemia? Evidence From Paired Peripheral Blood and Bone Marrow Cytogenetics
作者
Mohammed Al Kurnas; Muluken Megiso; Ayalew Tefferi; Xi Zhang; Kebede H. Begna展开收起
作者单位
1. Department of Internal Medicine Mayo Clinic Rochester Minnesota USA; 2. Department of Internal Medicine Jefferson Einstein Philadelphia Hospital Philadelphia Pennsylvania USA; 3. Department of Internal Medicine, Division of Hematology Mayo Clinic Rochester Minnesota USA; 4. Department of Laboratory Medicine and Pathology, Division of Hematopathology Mayo Clinic Rochester Minnesota USA展开收起
46
天
Longitudinal Kidney Function Trajectories and Their Association With Hemoglobin and Transfusion Phenotype in Adults With β‐Thalassemia
作者
Barbara Gianesin; Rodolfo Russo; Giovanni Battista Ferrero; Filomena Longo; Susanna Barella; Raffaella Origa; Roberto Lisi; Roberta Sciortino; Annamaria Pasanisi; Ilaria Foggetti; Eugenia Mariani; Giovan Battista Ruffo; Valeria Maria Pinto; Gian Luca Forni展开收起
作者单位
1. FORANEMIA ETS Foundation Genoa Italy; 2. Clinica Nefrologica, Dialisi e Trapianto IRCCS Azienda Ospedaliera Metropolitana Policlinico Ospedale San Martino Genoa Italy; 3. SSD Microcitemie e Malattie Rare Ematologiche Ospedale San Luigi Gonzaga, Orbassano Torino Italy; 4. Day Hospital Della Talassemia e Delle Emoglobinopatie Azienda Ospedaliero Universitaria di Ferrara Ferrara Italy; 5. S.C. Centro Delle Microcitemie e Anemie Rare ARNAS G. Brotzu Cagliari Italy; 6. Department of Medical Sciences and Public Health University of Cagliari Cagliari Italy; 7. UOD Talassemia ARNAS Garibaldi Catania Italy; 8. Centro Microcitemia “A. Quarta” Ospedale “A. Perrino” Brindisi Italy; 9. Hematology Unit IRCCS Giannina Gaslini Genoa Italy; 10. UO Ematologia Ospedale Civico Palermo Italy; 11. Hematology and Cellular Therapy Unit IRCCS Azienda Ospedaliera Metropolitana Policlinico Ospedale San Martino Genoa Italy展开收起
83
天
Distinct Consequences of BCOR and BCORL1 Mutations in Myeloid Neoplasms and Bone Marrow Failure
作者
Atsushi Marumo; Arda Durmaz; Christopher Haddad; Aashray Mandala; Felipe de Almeida Sartori; Akram Abushamma; Serhan Unlu; Xiaorong Gu; Zachary Brady; Matteo D'Addona; Kartik Lakhotiya; Luca Guarnera; Masanori Yoshida; Monika M. Toma; Mark D. Orland; Carlos Bravo‐Perez; Carmelo Gurnari; Koichi Takahashi; Tomasz Skorski; Stephan Hutter; Torsten Haferlach; Marcin Wlodarski; Valeria Visconte; Jaroslaw P. Maciejewski展开收起
作者单位
1. Department of Translational Hematology and Oncology Research Taussig Cancer Institute, Cleveland Clinic Cleveland Ohio USA; 2. Department of Hematology Graduate School of Medicine, Nippon Medical School Tokyo Japan; 3. Hematology and Transplant Center, University Hospital “San Giovanni di Dio e Ruggi D'aragona” Salerno Italy; 4. Hematology, Department of Biomedicine and Prevention University of Rome Tor Vergata Rome Italy; 5. Department of Pediatric Hematology and Oncology Research Research Institute, National Center for Child Health and Development Tokyo Japan; 6. Fels Cancer Institute for Personalized Medicine, Temple University Lewis Katz School of Medicine Philadelphia Pennsylvania USA; 7. Department of Hematology and Medical Oncology Hospital Universitario Morales Meseguer, University of Murcia, IMIB‐Pascual Parrilla, CIBERER – Instituto de Salud Carlos III Murcia Spain; 8. Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA; 9. Department of Cancer and Cellular Biology Temple University Lewis Katz School of Medicine Philadelphia Pennsylvania USA; 10. Nuclear Dynamics and Cancer Program, Fox Chase Cancer Center Philadelphia Pennsylvania USA; 11. MLL Munich Leukemia Laboratory Munich Germany; 12. St. Jude Children's Research Hospital, Department of Hematology Memphis USA展开收起
35
天
New Drugs in Myelofibrosis: Incremental Progress in Symptom Management Without Disease Modification
作者
Naseema Gangat; Paola Guglielmelli; Alessandro M. Vannucchi; Ayalew Tefferi展开收起
作者单位
1. Division of Hematology Mayo Clinic Rochester Minnesota USA; 2. Department of Experimental and Clinical Medicine, CRIMM, Center Research and Innovation of Myeloproliferative Neoplasms Azienda Ospedaliera Universitaria Careggi, University of Florence Florence Italy展开收起
FAQ
AMERICAN JOURNAL OF HEMATOLOGY审稿要多久?
截至2026-11-17,CrushSCI 收录了 AMERICAN JOURNAL OF HEMATOLOGY 的 30 篇完整审稿记录。最快一篇从收稿到录用用了 3 天(Myelodysplastic Syndromes: 2026 Update on Diagnosis, Risk‐Stratification and Management,2026-04-01 收稿,2026-04-04 录用),最慢一篇用了 236 天;平均 51.4 天,中位数 34 天。最快这篇的日期间隔异常短,建议点开原文核对。
Expert Matching · Case Demo
把投稿要求,转成可验证的期刊方案
说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。
